未找到相关数据
Anlotinib combined with penpulimab as first-line treatment for persistent, recurrent, or metastatic cervical cancer: Preliminary results from ALTER-GO-020, a single-arm, open-label, multi-cohort, multi-center phase II clinical study.
被引：0
作者：
Wang, Dengfeng
Liu, Hong
Chen, Lihong
He, Mian
Zhao, Weidong
Xiang, Yang
Zhang, Guonan
机构：
[1] Univ Elect Sci & Technol China, Sichuan Clin Res Ctr Canc, Sichuan Canc Hosp & Inst, Sichuan Canc Ctr,Affiliated Canc Hosp, Chengdu, Peoples R China
[2] Shanxi Prov Peoples Hosp, Xian, Peoples R China
[3] Sun Yat Sen Univ, Affiliated Hosp 1, Guangzhou, Peoples R China
[4] USTC, Anhui Prov Hosp, Affiliated Hosp 1, Hefei, Peoples R China
[5] Peking Union Med Coll Hosp, Beijing, Peoples R China
[6] Univ Elect Sci & Technol China, Sch Med, Affiliated Canc Hosp, Sichuan Canc Hosp & Inst,Sichuan Canc Ctr, Chengdu, Peoples R China
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17506
引用
收藏
页数：1
相关论文